Post by ROTOP Pharmaka GmbH

New Milestone: RoTecPSMA® Approved in Switzerland We are delighted to announce that RoTecPSMA® has received marketing authorization in Switzerland, marking another significant step in broadening patient access to our innovative PSMA SPECT agent. This new approval comes in collaboration with our trusted Swiss partner and marketing authorization holder medeo AG, who will oversee distribution and support across the region. The authorization underlines the exceptional quality and diagnostic value of RoTecPSMA® in theranostics, reinforcing our ongoing commitment to delivering advanced care solutions to patients and healthcare professionals alike. Following the approval, we are now advancing preparations for a well-coordinated market introduction of RoTecPSMA® in Switzerland. Availability will follow in alignment with these ongoing efforts. We look forward to a fruitful partnership with medeo AG and to seeing RoTecPSMA® make a meaningful impact in Switzerland. More information: https://lnkd.in/dVJu9GMJ #rotop #RoTecPSMA #prostatecancer #SPECT #theranostics